Zenas BioPharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZBIO | ZYME | ZURA | ZNTL | ZLAB | XNCR | |
|---|---|---|---|---|---|---|
| Market cap | 1.85B | 2.22B | 387.23M | 172.69M | 2.83B | 2.60B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.1 | 25.5 | -5.9 | -1.0 | -10.9 | -9.9 |
| Price/book | 7.3 | 27.5 | 2.2 | 0.9 | 4.2 | 4.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −7.04% | +72.85% | +15.52% | +32.84% | −11.45% | +150.21% |
| Today | +0.28% | +2.69% | +0.75% | −1.12% | +3.83% | +14.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ZBIO news ›Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development October 27, 2026 8:00 AM EDT Abigail Lee Gray - Director of Investor RelationsLeon Moulder - Founder, CEO & ChairmanHaley Laken - Chief Scientific OfficerLisa…
BlackRock Reports 5% Ownership Stake in Zenas BioPharma Common Stock
What Could Pfizer (NYSE:PFE) Reveal About Its Next Growth Chapter? What Is Driving Bank of America (NYSE:BAC) Forward This Quarter? How Is Wells Fargo (NYSE:WFC) Growing After Its Asset Cap Ended? Why Is Enphase Energy (NASDAQ:ENPH)…
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)
Posted by Danessa Lincoln on Oct 18th, 2026 Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both healthcare companies, but which is the better stock? We will…
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Manila Times The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of October 15, 2027, October 15, 2028, Oc
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Stock Has Average Price Target of $46.71 According to Brokerages
Posted by Mitch Edgeman on Oct 17th, 2026 Read Our Latest Analysis on ZBIO Shares of ZBIO opened at $24.84 on Monday. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The firm’s 50 day moving average is $30.16…
Galderma buys ZO Skin Health for $1.5B in cash from Blackstone, Obagi family
Galderma’s $1.5B all-cash buy of ZO Skin Health boosts its US physician-dispensed skincare reach and EPS outlook. Torsten Asmus/iStock via Getty Images - Galderma Group AG (GALDY) has agreed to acquire ZO Skin Health Inc. in an all-cash…
Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related disease
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Zenas BioPharma releases Phase 3 obexelimab data in IgG4-related…
Zenas BioPharma announces new obexelimab data
UnitedHealth Group Reports Third Quarter 2026 Results Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2026 (Former name or former address, if changed…
Galderma Said to Buy Blackstone-owned ZO Skin Health for $1.5 Billion
Galderma Group agreed to acquire skincare brand ZO Skin Health from alternative asset manager Blackstone, Reuters reported Wednesday, citing two people familiar with the matter. The deal is... Galderma Said to Buy Blackstone-owned ZO Skin…
Zenas BioPharma Announces Sustained Clinical Activity and Reduced Glucocorticoid Toxicity for Obexelimab in Phase 3 INDIGO IgG4-RD Extension Study
Phase 3 INDIGO findings show obexelimab's sustained activity and reduced glucocorticoid toxicity in IgG4-RD patients. The Phase 3 INDIGO trial showed sustained clinical activity of obexelimab, with fewer patients experiencing…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- marketscreener.com3
- stocktitan.net3
- manilatimes.net2
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.